Sanofi stock holds firm on vaccine updates and June quarter growth

Published on 09/01/2026 at 18:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock stays supported by vaccine updates and a June 30, 2026 quarter that showed revenue of $11.95 billion, up 12.2 percent year over year, even as EPS eased to $0.35.

Aquarellmalerei der Pariser Skyline mit Eiffelturm und Seine bei Sonnenuntergang — Vivendi SE (FR0000127771) hat ihren Hauptsitz in Paris; das Aquarell zeigt die Seine bei Sonnenuntergang, Illustration mit AI erstellt.

Sanofi stock (FR0000127771) closed at EUR 77.25 on August 28, 2026, while the US-quoted share price was $44.82 on August 29, 2026 and the market value stood at $107.39 billion. The latest quarterly update gave the French drugmaker a clear operating split: revenue rose 12.2 percent year over year to $11.95 billion, but EPS slipped to $0.35 from $0.39.

Vaccines keep the story moving

Recent reporting on August 31, 2026 tied Sanofi to the 2026-27 COVID vaccine rollout, with updated shots aimed at the XFG variant. That keeps vaccines in the foreground for investors as the share price sits near its recent Paris close rather than at a fresh high.

The market backdrop is also less forgiving than earlier in the year. Sanofi was still 6.61 percent lower for the year at the August 28 Paris close, according to the market snapshot, which means the June quarter has to do more than simply confirm steady sales.

Revenue up, EPS softer

The June 30, 2026 quarter shows why the stock has not turned into a pure momentum trade. Revenue increased by $1.30 billion from $10.65 billion in the prior-year quarter, while EPS declined by $0.04 year over year to $0.35.

That mix points to margin and product mix as the main investor questions, not top-line growth alone. For a group with a $107.39 billion market capitalization, the market is already paying for scale, so the next move depends on whether profits can catch up with sales.

Go deeper

Dupixent and vaccines

Sanofi's product mix still hinges on large franchises, and the vaccine update adds another operating lever for the second half of 2026.

Sanofi overview

Dupixent still matters

Dupixent remains the best-known growth pillar in Sanofi's portfolio, but the current market discussion is broader than one product. Investors are watching whether the vaccine update and the June quarter can support a steadier rerating after the stock's year-to-date decline.

Stock level stays relevant

As of August 29, 2026, the US quote was $44.82 and the market capitalization was $107.39 billion. The Paris close of EUR 77.25 on August 28, 2026 keeps Sanofi stock in a range where the market is still waiting for profits to move closer to sales growth.